Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 3/20 | 0.31 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20568482 | 0.85 | BRAF (0.36) | BRAFPTGS2MEN1KMT2ASCN9A | |
| SCHEMBL23348206 | 0.85 | STK10 (0.34) | PTGS2MAPK14SCN9A | |
| SCHEMBL20569068 | 0.82 | PDE3B (0.35) | PTGS2SCN9ACYP1A2 | |
| SCHEMBL23348173 | 0.77 | GCGR (0.39) | MAPK14MEN1KMT2APDE10AGCGR | |
| SCHEMBL29750710 | 0.76 | SCN9A (0.35) | BRAFPTGS2MAPK14SCN9ACYP1A2 | |
| SCHEMBL23327335 | 0.73 | STK10 (0.34) | MAPK14SCN9A | |
| SCHEMBL23348207 | 0.72 | GCGR (0.46) | MAPK14MEN1KMT2AGCGRCYP1A2 | |
| SCHEMBL20568466 | 0.69 | STK10 (0.34) | SCN9A | |
| SCHEMBL30794689 | 0.69 | KDM4E (0.53) | MEN1KMT2A | |
| SCHEMBL29750721 | 0.65 | TRPA1 (0.34) | PTGS2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, ALPI | BRAF 3848/4885PTGS2 1305/4885MAPK14 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.